How controlling of hypertension might matter

Circulation Journal

Volumn 73, Issue 12, 2009, Pages 2208-2209

  Hara, Kazuo ^a   Kadowaki, Takashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE MARKER; DRUG EFFECT; EDITORIAL; ESSENTIAL HYPERTENSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MOLECULAR WEIGHT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CILAZAPRIL; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; INDAPAMIDE; INSULIN; LIPIDS; PERINDOPRIL; TIME FACTORS; TREATMENT OUTCOME;

EID: 73349085891     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0808     Document Type: Editorial

References (15)

1. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
2. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, et al; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-2788.
3. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
4. Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: More efficacious than individual agents-a preliminary report. Hypertension 2007; 49: 272-275.
5. Huang SS, Wu TC, Lin SJ, Chen JW. Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J 2009; 73: 2282-2287.
6. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009; 73: 608-614.
7. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
8. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
9. Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Acikel C, et al. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 2005; 99: c115-c121.
10. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99: 1006-1012.
11. Piecha G, Adamczak M, Chudek J, Wiecek A. Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Press Res 2007; 30: 187-194.
12. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
13. Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, et al; COLM study investigators. Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res 2009; 32: 163-167.
14. Ogihara T, Matsuzaki M, Matsuoka H, Shimamoto K, Shimada K, Rakugi H, et al; COPE Trial Group. The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: Rationale and design. Hypertens Res 2005; 28: 331-338.
15. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007; 370: 829-840.